{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:00Z","timestamp":1786987020679,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clml.2026.03.016","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:21:35Z","timestamp":1774628495000},"page":"e802-e810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies"],"prefix":"10.1016","volume":"26","author":[{"given":"Issam S.","family":"Hamadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximillian","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5798-6427","authenticated-orcid":false,"given":"Lisa","family":"Modelevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Lesokhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin L.","family":"Hultcrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlyn R.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Hassoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvi A.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylee","family":"Maclachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridevi","family":"Rajeeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross S.","family":"Firestone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhwani","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1189","authenticated-orcid":false,"given":"Heather J.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Korde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2026.03.016_bib0001","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2026.03.016_bib0002","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.clml.2026.03.016_bib0003","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2026.03.016_bib0004","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"issue":"22","key":"10.1016\/j.clml.2026.03.016_bib0005","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.016_bib0006","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","author":"Costa","year":"2025","journal-title":"N Engl J Med"},{"issue":"Suppl.1","key":"10.1016\/j.clml.2026.03.016_bib0007","first-page":"654","article-title":"Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) trial","volume":"144","author":"Raab","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.016_bib0008","article-title":"Dual targeting of extramedullary myeloma with talquetamab and teclistamab","author":"Shaji Kumar","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2026.03.016_bib0009","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell-engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.clml.2026.03.016_bib0010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.clml.2026.03.016_bib0011","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clml.2026.03.016_bib0012","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2026.03.016_bib0013","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2026.03.016_bib0014","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"issue":"19","key":"10.1016\/j.clml.2026.03.016_bib0015","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/bloodadvances.2025016911","article-title":"Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies","volume":"9","author":"Kowalski","year":"2025","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.clml.2026.03.016_bib0016","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1002\/hem3.132","article-title":"Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed\/refractory myeloma patients treated with teclistamab: implications for outpatient step-up dosing","volume":"8","author":"Korst","year":"2024","journal-title":"Hemasphere"},{"issue":"suppl. 16","key":"10.1016\/j.clml.2026.03.016_bib0017","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1200\/JCO.2023.41.16_suppl.8033","article-title":"Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1","volume":"41","author":"van de Donk","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.03.016_bib0018","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41408-023-00963-y","article-title":"Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience","volume":"13","author":"Scott","year":"2023","journal-title":"Blood Cancer J"},{"issue":"Suppl.1","key":"10.1016\/j.clml.2026.03.016_bib0019","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1182\/blood-2025-718","article-title":"Real-world use, safety, and efficacy of teclistamab with or without prophylactic tocilizumab in relapsed\/refractory multiple myeloma; results from the danish ABCD study","volume":"146","author":"Torpe","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.016_bib0020","unstructured":"National Comprehensive Cancer Network. (2025). NCCN clinical practice guidelines in oncology: multiple myeloma (Version 4.2026). https:\/\/www.nccn.org. Accessed April 19, 2026."},{"key":"10.1016\/j.clml.2026.03.016_bib0021","unstructured":"Tocilizumab. South San Francisco, CA: Genentech, Inc; 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125276s149lbl.pdf. Accessed April 19, 2026."},{"key":"10.1016\/j.clml.2026.03.016_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcrc.2023.154291","article-title":"Low dose vs high dose tocilizumab in COVID-19 patients with hypoxemic respiratory failure","volume":"76","author":"Chung","year":"2023","journal-title":"J Crit Care"},{"key":"10.1016\/j.clml.2026.03.016_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100459","article-title":"Early use of low dose tocilizumab in patients with COVID-19: a retrospective cohort study with a complete follow-up","volume":"25","author":"De Rossi","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"12","key":"10.1016\/j.clml.2026.03.016_bib0024","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/bloodadvances.2024012724","article-title":"Patterns of CRS with teclistamab in relapsed\/refractory multiple myeloma with or without prior T-cell redirection therapy","volume":"8","author":"Hamadeh","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2026.03.016_bib0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:05:33Z","timestamp":1781251533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2152265026000935"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}